Latest long-term debt for ENOB: $130K.
Get informed when a big investor buys or sells
+ FollowLatest change versus the prior comparable period (same company).
As of the most recent data (March 2026), ENOB shows a long-term debt of $130K. That compares with $500K in the prior-year period — down 73.6% year over year. Scroll down for historical charts and peer comparison views.
Compared with the year-ago period, ENOB's long-term debt is now $130K (was $500K) — a 73.6% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether Enochian Biosciences is outperforming or lagging.
Tracking ENOB's long-term debt over time shows whether Enochian Biosciences is scaling, shrinking, or reshaping that part of the business. The current reading is $130K That compares with $500K in the prior-year period — down 73.6% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.
Besides this long-term debt page, Stockcircle has Enochian Biosciences's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect long-term debt (currently $130K) with ownership activity and broader fundamentals.
Enochian Biosciences's long-term debt is $130K; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.